摘要
目的检测晚期非小细胞肺癌患者化疗前后血清肿瘤标志物水平的改变。方法 52例接受化疗的晚期非小细胞肺癌患者列为观察组。另纳入同期健康体检者45例作为对照组。检测观察组治疗前后及对照组外周血前梯度同源蛋白2(AGR2)、可溶性白细胞介素-2受体(SIL-2R)及血清胸苷激酶1(TK1)水平。结果观察组患者疗效为完全缓解(1级)0例,部分缓解(2级)16例,稳定(3级)19例及进展(4级)17例。化疗后,观察组患者外周血AGR2、SIL-2R及TK1水平均较化疗前显著降低(P<0.05)。观察组患者化疗2周期后外周血AGR2、SIL-2R及TK1水平与化疗效果等级均呈现显著正相关(P<0.05)。结论血清AGR2、SIL-2R及血清TK1在晚期非小细胞肺癌化疗后显著降低,且下降水平与化疗效果相关。
Objective To detect the changes of serum tumor markers before and after chemotherapy in patients with advanced non-small cell lung cancer. Methods Fifty-two patients with advanced non-small cell lung cancer by chemotherapy were selected as observation group,and forty-five healthy controls were selected as control group. Peripheral blood anterior gradient precursor protein 2（ AGR2）,soluble interleukin-2 receptor（ SIL-2R） and serum thymidine kinase 1（ TK1） levels were detected before and after treatment in both groups. Results The curative effects of the observation group were 0 case of complete remission（ grade 1）,16 cases of partial remission（ grade 2）,19 cases of stability（ grade 3） and 17 cases of progression（ grade 4）. After treatment,the levels of AGR2,SIL-2Rand TK1 decreased significantly in observation group（ P〈0. 05）. Correlation analysis showed that after two cycles of treatment,the levels of AGR2,SIL-2R and TK1 were positively correlated with the therapeutic effect grade（ P〈0. 05）. Conclusion AGR2,SIL-2R and TK1 reduce significantly after chemotherapy in patients with advanced non-small cell lung cancer,and its decreasing level is correlated with chemotherapy effect.
出处
《实用临床医药杂志》
CAS
2017年第13期26-28,共3页
Journal of Clinical Medicine in Practice
基金
湖北省武汉市卫生局临床医学科研项目(WX12D13)
